<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publications</publisher-name><publisher-loc>Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28523031</article-id><article-id pub-id-type="pmc">5432698</article-id><article-id pub-id-type="publisher-id">PJMS-33-325</article-id><article-id pub-id-type="doi">10.12669/pjms.332.12414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Myocardial protection with Glucose-Insulin-Potassium infusion during adult cardiac surgery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahmad</surname><given-names>Suhail</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Ahmad</surname><given-names>Rana Altaf</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Qureshi</surname><given-names>Bilal Ahsan</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Baig</surname><given-names>Mirza Ahmad Raza</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Dr. Suhail Ahmad, DA, MCPS, FCPS, M. Sc. Pain Medicine, Associate Professor of Anesthesia and Critical Care, CPE Institute of Cardiology Multan, Pakistan</aff><aff id="aff2"><label>2</label>Dr. Rana Altaf Ahmad, DA, FCPS, M. Sc. Pain Medicine, Professor of Anesthesia and Critical Care, Executive Director, CPE Institute of Cardiology Multan, Pakistan</aff><aff id="aff3"><label>3</label>Dr. Bilal Ahsan Qureshi, Associate Professor of Cardiology, CPE Institute of Cardiology Multan, Pakistan</aff><aff id="aff4"><label>4</label>Mirza Ahmad Raza Baig, B. Sc. Hons CPT, Clinical Perfusionist, CPE Institute of Cardiology Multan, Pakistan</aff><author-notes><corresp id="cor1">
Correspondence: Dr. Suhail Ahmad, DA, MCPS, FCPS, M. Sc. Pain Medicine, Associate Professor of Anesthesia and Critical Care, 11-Allah Buksh Colony, Near Shamsabad Colony, Multan, Pakistan. E-mail: <email xlink:href="syedsuhailahmad@gmail.com">syedsuhailahmad@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2017</year></pub-date><volume>33</volume><issue>2</issue><fpage>325</fpage><lpage>329</lpage><history><date date-type="received"><day>24</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>04</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>12</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: © Pakistan Journal of Medical Sciences</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3822" xml_f="3849" txt_i="11" txt_f="34">Background &amp; Objective:</offsets></title><p><offsets xml_i="3860" xml_f="4177" txt_i="35" txt_f="352">Recent meta-analysis reports have called for more randomized trials to evaluate the effectiveness of GIK solution in patients of cardiac surgery. So this study was conducted to evaluate the effectiveness of Glucose-insulin-potassium (GIK) solutions in non-diabetic patients undergoing coronary artery bypass grafting.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4208" xml_f="4216" txt_i="354" txt_f="362">Methods:</offsets></title><p><offsets xml_i="4227" xml_f="4701" txt_i="363" txt_f="837">A total number of one hundred and sixty (160) patients were randomized into two equal groups; GIK Group and non-GIK group. In GIK group, 5% dextrose containing 70 IU/L regular insulin and 70 meq/L of potassium was administered. The infusion was started at a rate of 30 ml/hour after induction of anesthesia and before the start of cardiopulmonary bypass. The infusion was started again after removal of aortic cross clamp and was continued for six hours after the operation.</offsets></p></sec><sec id="st3"><title><offsets xml_i="4732" xml_f="4740" txt_i="839" txt_f="847">Results:</offsets></title><p><offsets xml_i="4751" xml_f="5474" txt_i="848" txt_f="1568">In early post-operative period, peak CKMB levels were high in non-GIK group 48.50±19.79 IU/L versus 33.40±14.69 IU/L in GIK group (p-value &lt;0.001). There was no statistically significant difference in requirements of inotropic support between the groups. The mean duration of inotropic support in GIK group was only 5.50±6.88 hours in GIK group and 8.64±7.74 hours in non-GIK group (p-value 0.008). Mean ventilation time in GIK group was 5.06±2.39 hours versus 6.55±3.58 hours in non-GIK group (p-value 0.002). Similarly, ICU stay period was also shorter in GIK group (p-value 0.01). We did not found any detrimental effect of GIK infusion on non-cardiac complications e.g. renal, pulmonary and neurologic complications.</offsets></p></sec><sec id="st4"><title><offsets xml_i="5505" xml_f="5516" txt_i="1570" txt_f="1581">Conclusion:</offsets></title><p><offsets xml_i="5527" xml_f="5726" txt_i="1582" txt_f="1781">Glucose-insulin-potassium (GIK) infusion has a beneficial role in myocardial protection and is associated with better post-operative outcomes without increasing the risk of non-cardiac complications.</offsets></p></sec></abstract><kwd-group><kwd>Coronary artery bypass grafting</kwd><kwd>Glucose-insulin-potassium (GIK) solution</kwd><kwd>Myocardial protection</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5965" xml_f="5977" txt_i="1790" txt_f="1802">INTRODUCTION</offsets></title><p><offsets xml_i="5988" xml_f="6071" txt_i="1803" txt_f="1886">Use of glucose insulin and potassium (GIK) solution for myocardial protection was 1</offsets><sup><offsets xml_i="6076" xml_f="6078" txt_i="1886" txt_f="1888">st</offsets></sup><offsets xml_i="6084" xml_f="6290" txt_i="1888" txt_f="2094"> time introduced by Sodi-Pollares and colleagues. They used this solution in patients with acute myocardial infarction and concluded that GIK solution limited electrocardiographic changes in these patients.</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="6323" xml_f="6324" txt_i="2094" txt_f="2095">1</offsets></xref><offsets xml_i="6331" xml_f="6444" txt_i="2095" txt_f="2208"> Several studies have shown reduced morbidity and mortality in patients of acute MI with the use of GIK solution.</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="6477" xml_f="6478" txt_i="2208" txt_f="2209">2</offsets></xref><offsets xml_i="6485" xml_f="6486" txt_i="2209" txt_f="2210">,</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6519" xml_f="6520" txt_i="2210" txt_f="2211">3</offsets></xref><offsets xml_i="6527" xml_f="6631" txt_i="2211" txt_f="2315"> A meta-analysis report calculated that in-hospital mortality is reduced by 28% in patients of acute MI.</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="6664" xml_f="6665" txt_i="2315" txt_f="2316">4</offsets></xref><offsets xml_i="6672" xml_f="6822" txt_i="2316" txt_f="2466"> Early Studies in isolated hearts have concluded that GIK solution infusion is associated with reduced infarct size and improved ventricular function.</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="6855" xml_f="6856" txt_i="2466" txt_f="2467">5</offsets></xref><offsets xml_i="6863" xml_f="6864" txt_i="2467" txt_f="2468">,</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="6897" xml_f="6898" txt_i="2468" txt_f="2469">6</offsets></xref></p><p><offsets xml_i="6912" xml_f="7095" txt_i="2470" txt_f="2653">The role of GIK solution in cardiac surgery patients has also been investigated and studies have proven its efficacy in reducing mortality and improvement in post-operative morbidity.</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="7128" xml_f="7129" txt_i="2653" txt_f="2654">7</offsets></xref><offsets xml_i="7136" xml_f="7137" txt_i="2654" txt_f="2655">-</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="7171" xml_f="7173" txt_i="2655" txt_f="2657">10</offsets></xref><offsets xml_i="7180" xml_f="7513" txt_i="2657" txt_f="2990"> During coronary artery bypass grafting (CABG), the myocardium is subjected to endure the periods of ischemia and reperfusion which may result in post-ischemia contractile dysfunction. That is a major contributor of early and late morbidity and mortality and increased requirement of pharmacologic and mechanical circulatory support.</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="7547" xml_f="7549" txt_i="2990" txt_f="2992">11</offsets></xref><offsets xml_i="7556" xml_f="7557" txt_i="2992" txt_f="2993">,</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="7591" xml_f="7593" txt_i="2993" txt_f="2995">12</offsets></xref><offsets xml_i="7600" xml_f="7817" txt_i="2995" txt_f="3212"> Meta-analysis by Bothe et al involving 11 randomized trials concluded that GIK administration associated with improved post-operative contractile function and reduced risk of atrial arrhythmias after cardiac surgery.</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="7851" xml_f="7853" txt_i="3212" txt_f="3214">13</offsets></xref><offsets xml_i="7860" xml_f="8262" txt_i="3214" txt_f="3616"> Most of these studies were conducted in diabetic patients and few studies have been conducted in non-diabetic patients regarding effectiveness of GIK solution in cardiac surgery patients. In this clinical trial we evaluated the effectiveness of GIK solutions regarding myocardial protection and early post-operative surgery outcomes in non-diabetic patients undergoing coronary artery bypass grafting.</offsets></p></sec><sec sec-type="methods" id="sec1-2"><title><offsets xml_i="8315" xml_f="8322" txt_i="3618" txt_f="3625">METHODS</offsets></title><p><offsets xml_i="8333" xml_f="9338" txt_i="3626" txt_f="4628">This prospective randomized clinical trial was conducted in three months period from March 2016 to June 2016. A total number of one hundred and sixty (160) patients were randomized into two equal groups. Computer generated random numbers were used to assign patients into study and control group. Group-I (GIK group); in this group of patients glucose insulin and potassium infusion was given during surgery and Group-II (non-GIK group); in these patients only glucose infusion was given during the procedure. Initial approval for use of GIK solution in cardiac surgery patients was taken from the department of academic affairs of CPE institute of cardiology. Informed consent was taken before surgery from every patient. Patients of age more than 30 years who underwent multi-vessel coronary artery bypass grafting were selected. Diabetic patients, patients with pre-operative renal dysfunction (creatinine&gt;1.2 mg/dl), valvular operations, those with previous stroke and emergency CABG were excluded.</offsets></p><p><offsets xml_i="9345" xml_f="10285" txt_i="4629" txt_f="5566">Draw randomization was used to assign individuals to study and control groups. For study group patients, GIK solutions was prepared before induction of anesthesia by adding 70 IU of regular insulin and 70 meq of potassium in 5% dextrose of 1000 ml and the infusion was started at a rate of 30 ml/hour. In control group, only 5% dextrose infusion was given at 30 ml/hour. The infusion was started after induction of anesthesia and before the start of cardiopulmonary bypass. The infusion was started again after removal of aortic cross clamp and was continued for six hours after the operation. In non-GIK group only dextrose 5% infusion was given in the same manner as that in GIK group. In this group blood glucose levels were controlled using following protocol; RBS 80 to &lt;200=no need for insulin, RBS 200 to 300= 5 units of regular insulin, RBS 300-400=7 units regular insulin, 400-500= 10 units regular insulin given subcutaneously.</offsets></p><p><offsets xml_i="10292" xml_f="10614" txt_i="5567" txt_f="5889">Coronary artery grafting was done after establishing standard cardiopulmonary bypass. After clamping the aorta, cold blood cardioplegia was used to arrest the heart and was repeated after completion of each distal graft. Left internal mammary artery was used to vascularize left anterior descending artery in all patients.</offsets></p><p><offsets xml_i="10621" xml_f="10802" txt_i="5890" txt_f="6071">Serum potassium and glucose levels were measured before staring the GIK infusion and after every two hours of unclamping the aorta. Standard 12 lead electrocardiogram was taken on 1</offsets><sup><offsets xml_i="10807" xml_f="10809" txt_i="6071" txt_f="6073">st</offsets></sup><offsets xml_i="10815" xml_f="10821" txt_i="6073" txt_f="6079"> and 2</offsets><sup><offsets xml_i="10826" xml_f="10828" txt_i="6079" txt_f="6081">nd</offsets></sup><offsets xml_i="10834" xml_f="11195" txt_i="6081" txt_f="6439"> day after surgery. Post-op CKMB levels were measured after 6, 12 and 24 hours and peak levels were noted. Appearance of Q wave and ST elevation &gt; 1 mm and increase in CK-MB levels more than 125 IU was recorded as perioperative myocardial infarction. Requirement of inotropic support on weaning and in immediate period after cardiopulmonary bypass was noted.</offsets></p><p><offsets xml_i="11202" xml_f="11257" txt_i="6440" txt_f="6495">The following criteria were used to classify inotropes:</offsets></p><p><offsets xml_i="11264" xml_f="11265" txt_i="6496" txt_f="6497">
</offsets><list list-type="roman-lower"><list-item><p><bold><offsets xml_i="11315" xml_f="11319" txt_i="6497" txt_f="6501">Mild</offsets></bold><offsets xml_i="11326" xml_f="11349" txt_i="6501" txt_f="6521"> = Dobutamine&lt;5µg.kg</offsets><sup><offsets xml_i="11354" xml_f="11356" txt_i="6521" txt_f="6523">-1</offsets></sup><offsets xml_i="11362" xml_f="11365" txt_i="6523" txt_f="6526">min</offsets><sup><offsets xml_i="11370" xml_f="11372" txt_i="6526" txt_f="6528">-1</offsets></sup><offsets xml_i="11378" xml_f="11426" txt_i="6528" txt_f="6573">, epinephrine or nor epinephrine &lt; 0.06 µg.kg</offsets><sup><offsets xml_i="11431" xml_f="11433" txt_i="6573" txt_f="6575">-1</offsets></sup><offsets xml_i="11439" xml_f="11442" txt_i="6575" txt_f="6578">min</offsets><sup><offsets xml_i="11447" xml_f="11449" txt_i="6578" txt_f="6580">-1</offsets></sup><offsets xml_i="11455" xml_f="11456" txt_i="6580" txt_f="6581">,</offsets></p></list-item><list-item><p><bold><offsets xml_i="11492" xml_f="11500" txt_i="6582" txt_f="6590">Moderate</offsets></bold><offsets xml_i="11507" xml_f="11530" txt_i="6590" txt_f="6613">= Dobutamine 5-10 µg.kg</offsets><sup><offsets xml_i="11535" xml_f="11537" txt_i="6613" txt_f="6615">-1</offsets></sup><offsets xml_i="11543" xml_f="11546" txt_i="6615" txt_f="6618">min</offsets><sup><offsets xml_i="11551" xml_f="11553" txt_i="6618" txt_f="6620">-1</offsets></sup><offsets xml_i="11559" xml_f="11604" txt_i="6620" txt_f="6665"> epinephrine or norepinephrine 0.06-1.0 µg.kg</offsets><sup><offsets xml_i="11609" xml_f="11611" txt_i="6665" txt_f="6667">-1</offsets></sup><offsets xml_i="11617" xml_f="11620" txt_i="6667" txt_f="6670">min</offsets><sup><offsets xml_i="11625" xml_f="11627" txt_i="6670" txt_f="6672">-1</offsets></sup></p></list-item><list-item><p><bold><offsets xml_i="11669" xml_f="11678" txt_i="6673" txt_f="6682">High dose</offsets></bold><offsets xml_i="11685" xml_f="11710" txt_i="6682" txt_f="6704">= Dobutamine&gt; 10 µg.kg</offsets><sup><offsets xml_i="11715" xml_f="11717" txt_i="6704" txt_f="6706">-1</offsets></sup><offsets xml_i="11723" xml_f="11726" txt_i="6706" txt_f="6709">min</offsets><sup><offsets xml_i="11731" xml_f="11733" txt_i="6709" txt_f="6711">-1</offsets></sup><offsets xml_i="11739" xml_f="11782" txt_i="6711" txt_f="6751">, epinephrine or norepinephrine &gt;1 µg.kg</offsets><sup><offsets xml_i="11787" xml_f="11789" txt_i="6751" txt_f="6753">-1</offsets></sup><offsets xml_i="11795" xml_f="11798" txt_i="6753" txt_f="6756">min</offsets><sup><offsets xml_i="11803" xml_f="11805" txt_i="6756" txt_f="6758">-1</offsets></sup><offsets xml_i="11811" xml_f="11812" txt_i="6758" txt_f="6759">.</offsets></p></list-item></list><offsets xml_i="11835" xml_f="11836" txt_i="6760" txt_f="6761">
</offsets></p><p><offsets xml_i="11843" xml_f="12118" txt_i="6762" txt_f="7037">The primary endpoints of this study were; increase in post-op CKMB levels, intensity and duration of inotropic support and mechanical ventilation time. And non-cardiac complications such as renal, pulmonary and neurologic complications were secondary endpoints of this study.</offsets></p><p><offsets xml_i="12125" xml_f="12274" txt_i="7038" txt_f="7187">The criteria to define pulmonary and renal complications in CPEIC cardiac surgery department is already defined in the study of Sher-i-Murtaza et al.</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="12308" xml_f="12310" txt_i="7187" txt_f="7189">14</offsets></xref><offsets xml_i="12317" xml_f="12822" txt_i="7189" txt_f="7694"> A two fold increase in serum creatinine levels from pre-op baseline value, or need for dialysis after surgery was labelled as renal complication. Occurrence of post-operative pleural effusion, acute respiratory distress syndrome or pneumothorax requiring either parecentesis or chest tube insertion were labelled as pulmonary complications. Occurrence of transient ischemic attacks, transient local paralysis, permanent local paralysis and permanent brain death were labelled as neurologic complications.</offsets></p><p><offsets xml_i="12829" xml_f="13057" txt_i="7695" txt_f="7920">Statistical analysis was done through SPSS v23 software. Quantitative variables were compared using t-test and qualitative variables through chi-square test. P-value &lt;0.05 was taken as cut of value for significant difference.</offsets></p></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="13110" xml_f="13117" txt_i="7922" txt_f="7929">RESULTS</offsets></title><p><offsets xml_i="13128" xml_f="13435" txt_i="7930" txt_f="8237">There was no significant difference between the mean age and gender of patients in the two groups. Severity of coronary artery disease and pre-operative ejection fraction was not different between the GIK and non-GIK groups. Frequency of risk factors of coronary artery disease was also same in two groups (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13465" xml_f="13470" txt_i="8237" txt_f="8242">Fig.1</offsets></xref><offsets xml_i="13477" xml_f="13637" txt_i="8242" txt_f="8402">). Regarding operative variables the mean number of grafts implanted, bypass time and cross-clamp time was also not significantly different between two groups (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="13669" xml_f="13676" txt_i="8402" txt_f="8409">Table-I</offsets></xref><offsets xml_i="13683" xml_f="13685" txt_i="8409" txt_f="8411">).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="13726" xml_f="13731" txt_i="8412" txt_f="8417">Fig.1</offsets></label><caption><p><offsets xml_i="13751" xml_f="13804" txt_i="8417" txt_f="8470">Comparison of risk factors of Ischemic Heart Disease.</offsets></p></caption><graphic xlink:href="PJMS-33-325-g001"></graphic></fig><table-wrap id="T1" position="float"><label><offsets xml_i="13917" xml_f="13924" txt_i="8471" txt_f="8478">Table-I</offsets></label><caption><p><offsets xml_i="13944" xml_f="13982" txt_i="8478" txt_f="8516">Patient’s baseline and operative data.</offsets></p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="center" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"><italic><offsets xml_i="14156" xml_f="14172" txt_i="8517" txt_f="8533">GIK Group (n=80)</offsets></italic></th><th align="center" rowspan="1" colspan="1"><italic><offsets xml_i="14237" xml_f="14257" txt_i="8533" txt_f="8553">Non-GIK Group (n=80)</offsets></italic></th><th align="center" rowspan="1" colspan="1"><italic><offsets xml_i="14322" xml_f="14329" txt_i="8553" txt_f="8560">P-value</offsets></italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14408" xml_f="14427" txt_i="8560" txt_f="8579">Age of Patients (Y)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14475" xml_f="14485" txt_i="8580" txt_f="8590">55.01±7.69</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14533" xml_f="14543" txt_i="8591" txt_f="8601">54.16±9.65</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14591" xml_f="14595" txt_i="8602" txt_f="8606">0.53</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14650" xml_f="14665" txt_i="8607" txt_f="8622">Male/Female (N)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14713" xml_f="14718" txt_i="8623" txt_f="8628">69/11</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14766" xml_f="14770" txt_i="8629" txt_f="8633">72/8</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14818" xml_f="14822" txt_i="8634" txt_f="8638">0.46</offsets></td></tr><tr><td align="left" colspan="3" rowspan="1"><italic><bold><offsets xml_i="14891" xml_f="14930" txt_i="8639" txt_f="8678">Severity of Coronary artery Disease (%)</offsets></bold></italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15001" xml_f="15022" txt_i="8679" txt_f="8700">Single vessel disease</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15070" xml_f="15077" txt_i="8701" txt_f="8708">0 (0.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15125" xml_f="15132" txt_i="8709" txt_f="8716">2 (2.5)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15180" xml_f="15184" txt_i="8717" txt_f="8721">0.32</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15239" xml_f="15257" txt_i="8722" txt_f="8740">Two vessel disease</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15305" xml_f="15314" txt_i="8741" txt_f="8750">36 (45.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15362" xml_f="15371" txt_i="8751" txt_f="8760">32 (40.0)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15426" xml_f="15447" txt_i="8761" txt_f="8782">Triple vessel disease</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15495" xml_f="15504" txt_i="8783" txt_f="8792">44 (55.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15552" xml_f="15561" txt_i="8793" txt_f="8802">46 (57.5)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15616" xml_f="15633" txt_i="8803" txt_f="8820">Ejection Fraction</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15681" xml_f="15691" txt_i="8821" txt_f="8831">53.12±9.13</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15739" xml_f="15749" txt_i="8832" txt_f="8842">52.06±9.83</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15797" xml_f="15801" txt_i="8843" txt_f="8847">0.48</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15856" xml_f="15866" txt_i="8848" txt_f="8858">EURO score</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15914" xml_f="15923" txt_i="8859" txt_f="8868">1.13±1.26</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15971" xml_f="15980" txt_i="8869" txt_f="8878">1.03±1.13</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16028" xml_f="16032" txt_i="8879" txt_f="8883">0.65</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16087" xml_f="16103" txt_i="8884" txt_f="8900">Number of grafts</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16151" xml_f="16159" txt_i="8901" txt_f="8909">3.0±0.50</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16207" xml_f="16215" txt_i="8910" txt_f="8918">2.9±0.84</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16263" xml_f="16267" txt_i="8919" txt_f="8923">0.43</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16322" xml_f="16343" txt_i="8924" txt_f="8945">Bypass time (minutes)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16391" xml_f="16403" txt_i="8946" txt_f="8958">110.56±26.00</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16451" xml_f="16463" txt_i="8959" txt_f="8971">105.82±25.40</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16511" xml_f="16515" txt_i="8972" txt_f="8976">0.24</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16570" xml_f="16590" txt_i="8977" txt_f="8997">Clamp time (minutes)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16638" xml_f="16649" txt_i="8998" txt_f="9009">64.19±16.73</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16697" xml_f="16707" txt_i="9010" txt_f="9020">62.15±17.6</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16755" xml_f="16759" txt_i="9021" txt_f="9025">0.45</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="16801" xml_f="17413" txt_i="9026" txt_f="9635">In early post-operative period, peak CKMB levels were high in non-GIK group 48.50±19.79 IU/L versus 33.40±14.69 IU/L in GIK group (p-value &lt;0.001). There was no statistically significant difference in requirements of inotropic support between the groups but the duration of inotropic support was longer in non-GIK group as compared to GIK group. Ventilator support period was also prolonged in GIK non-group (p-value 0.002). The stay of patients in ICU and hospital was also longer in non-GIK group. There was no difference in non-cardiac complications between the groups. There was no-in hospital mortality (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="17445" xml_f="17453" txt_i="9635" txt_f="9643">Table-II</offsets></xref><offsets xml_i="17460" xml_f="17462" txt_i="9643" txt_f="9645">).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="17510" xml_f="17518" txt_i="9646" txt_f="9654">Table-II</offsets></label><caption><p><offsets xml_i="17538" xml_f="17564" txt_i="9654" txt_f="9680">Early Post-operative Data.</offsets></p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="center" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"><italic><offsets xml_i="17738" xml_f="17754" txt_i="9681" txt_f="9697">GIK Group (n=80)</offsets></italic></th><th align="center" rowspan="1" colspan="1"><italic><offsets xml_i="17819" xml_f="17839" txt_i="9697" txt_f="9717">Non-GIK Group (n=80)</offsets></italic></th><th align="center" rowspan="1" colspan="1"><italic><offsets xml_i="17904" xml_f="17911" txt_i="9717" txt_f="9724">P-value</offsets></italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17990" xml_f="18013" txt_i="9724" txt_f="9747">Peak CKMB levels (IU/L)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18061" xml_f="18072" txt_i="9748" txt_f="9759">33.40±14.69</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18120" xml_f="18131" txt_i="9760" txt_f="9771">48.50±19.79</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18179" xml_f="18188" txt_i="9772" txt_f="9778">&lt;0.001</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18243" xml_f="18264" txt_i="9779" txt_f="9800">Peri-operative MI (%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18312" xml_f="18319" txt_i="9801" txt_f="9808">0 (0.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18367" xml_f="18374" txt_i="9809" txt_f="9816">1 (1.3)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18422" xml_f="18426" txt_i="9817" txt_f="9821">0.32</offsets></td></tr><tr><td align="left" colspan="3" rowspan="1"><italic><bold><offsets xml_i="18495" xml_f="18531" txt_i="9822" txt_f="9858">Requirement of Inotropic Support (%)</offsets></bold></italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18602" xml_f="18606" txt_i="9859" txt_f="9863">Mild</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18654" xml_f="18663" txt_i="9864" txt_f="9873">41 (51.2)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18711" xml_f="18720" txt_i="9874" txt_f="9883">36 (45.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18768" xml_f="18772" txt_i="9884" txt_f="9888">0.81</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18827" xml_f="18835" txt_i="9889" txt_f="9897">Moderate</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18883" xml_f="18892" txt_i="9898" txt_f="9907">21 (26.3)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18940" xml_f="18949" txt_i="9908" txt_f="9917">31 (38.8)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19004" xml_f="19013" txt_i="9918" txt_f="9927">High dose</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19061" xml_f="19068" txt_i="9928" txt_f="9935">3 (3.8)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19116" xml_f="19123" txt_i="9936" txt_f="9943">5 (6.3)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19178" xml_f="19215" txt_i="9944" txt_f="9981">Duration of Inotropic Support (hours)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19263" xml_f="19272" txt_i="9982" txt_f="9991">5.50±6.88</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19320" xml_f="19329" txt_i="9992" txt_f="10001">8.64±7.74</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19377" xml_f="19382" txt_i="10002" txt_f="10007">0.008</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19437" xml_f="19467" txt_i="10008" txt_f="10038">Total Ventilation time (hours)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19515" xml_f="19524" txt_i="10039" txt_f="10048">5.06±2.39</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19572" xml_f="19581" txt_i="10049" txt_f="10058">6.55±3.58</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19629" xml_f="19634" txt_i="10059" txt_f="10064">0.002</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19689" xml_f="19705" txt_i="10065" txt_f="10081">ICU stay (hours)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19753" xml_f="19764" txt_i="10082" txt_f="10093">35.29±11.46</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19812" xml_f="19823" txt_i="10094" txt_f="10105">43.48±26.28</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19871" xml_f="19875" txt_i="10106" txt_f="10110">0.01</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19930" xml_f="19950" txt_i="10111" txt_f="10131">Hospital Stay (Days)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19998" xml_f="20007" txt_i="10132" txt_f="10141">7.00±1.84</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20055" xml_f="20064" txt_i="10142" txt_f="10151">7.63±3.19</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20112" xml_f="20116" txt_i="10152" txt_f="10156">0.14</offsets></td></tr><tr><td align="left" colspan="3" rowspan="1"><italic><bold><offsets xml_i="20185" xml_f="20214" txt_i="10157" txt_f="10186">Non-cardiac Complications (%)</offsets></bold></italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20285" xml_f="20295" txt_i="10187" txt_f="10197">Neurologic</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20343" xml_f="20350" txt_i="10198" txt_f="10205">2 (2.5)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20398" xml_f="20405" txt_i="10206" txt_f="10213">1 (1.3)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20453" xml_f="20457" txt_i="10214" txt_f="10218">0.56</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20512" xml_f="20521" txt_i="10219" txt_f="10228">Pulmonary</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20569" xml_f="20576" txt_i="10229" txt_f="10236">3 (3.2)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20624" xml_f="20631" txt_i="10237" txt_f="10244">2 (2.5)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20679" xml_f="20683" txt_i="10245" txt_f="10249">0.65</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20738" xml_f="20743" txt_i="10250" txt_f="10255">Renal</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20791" xml_f="20795" txt_i="10256" txt_f="10260">----</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20843" xml_f="20848" txt_i="10261" txt_f="10266">-----</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20896" xml_f="20900" txt_i="10267" txt_f="10271">----</offsets></td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="20991" xml_f="21001" txt_i="10273" txt_f="10283">DISCUSSION</offsets></title><p><offsets xml_i="21012" xml_f="21212" txt_i="10284" txt_f="10484">For non-ischemic myocardial tissue the main energy source are free fatty acids that provide 60-70% of total myocardial demands. During ischemia these fatty acids are dangerous because these increase O</offsets><sub><offsets xml_i="21217" xml_f="21218" txt_i="10484" txt_f="10485">2</offsets></sub><offsets xml_i="21224" xml_f="21335" txt_i="10485" txt_f="10596">consumption, inhibit glucose consumption and predispose myocardium to arrhythmias with increased formation of O</offsets><sub><offsets xml_i="21340" xml_f="21341" txt_i="10596" txt_f="10597">2</offsets></sub><offsets xml_i="21347" xml_f="21362" txt_i="10597" txt_f="10612"> free radicals.</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="21396" xml_f="21398" txt_i="10612" txt_f="10614">15</offsets></xref><offsets xml_i="21405" xml_f="21502" txt_i="10614" txt_f="10711"> So provision of exogenous glucose substrate may prove beneficial for myocardium during ischemia.</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="21536" xml_f="21538" txt_i="10711" txt_f="10713">15</offsets></xref><offsets xml_i="21545" xml_f="21731" txt_i="10713" txt_f="10895"> GIK infusion can lead to metabolic modulation during ischemia &amp; reperfusion e.g. reduced free fatty acid oxidation, improved glucose oxidation, increase in glycolysis, increase in O</offsets><sub><offsets xml_i="21736" xml_f="21737" txt_i="10895" txt_f="10896">2</offsets></sub><offsets xml_i="21743" xml_f="21826" txt_i="10896" txt_f="10979"> uptake for ATP production and its utilization for better myocardial contractility.</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="21860" xml_f="21862" txt_i="10979" txt_f="10981">16</offsets></xref><offsets xml_i="21869" xml_f="21870" txt_i="10981" txt_f="10982">,</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="21904" xml_f="21906" txt_i="10982" txt_f="10984">17</offsets></xref><offsets xml_i="21913" xml_f="22146" txt_i="10984" txt_f="11217"> Moreover GIK also plays a role in insulin signaled K-ATP channels activation. These channels are an important mediators of ischemic pre-conditioning that is a powerful protector against ischemia reperfusion injury, MI and apoptosis.</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="22180" xml_f="22182" txt_i="11217" txt_f="11219">18</offsets></xref><offsets xml_i="22189" xml_f="22190" txt_i="11219" txt_f="11220">,</offsets><xref rid="ref19" ref-type="bibr"><offsets xml_i="22224" xml_f="22226" txt_i="11220" txt_f="11222">19</offsets></xref><offsets xml_i="22233" xml_f="22379" txt_i="11222" txt_f="11368"> Insulin plays a key role in the regulation of K-ATP channels by increasing the open state probability and by decreasing their sensitivity to ATP.</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="22413" xml_f="22415" txt_i="11368" txt_f="11370">20</offsets></xref><offsets xml_i="22422" xml_f="22504" txt_i="11370" txt_f="11452"> Moreover GIK infusion also reported to have vasodilator and inotropic properties.</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="22538" xml_f="22540" txt_i="11452" txt_f="11454">15</offsets></xref><offsets xml_i="22547" xml_f="22548" txt_i="11454" txt_f="11455">,</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="22582" xml_f="22584" txt_i="11455" txt_f="11457">21</offsets></xref></p><p><offsets xml_i="22598" xml_f="22803" txt_i="11458" txt_f="11663">Jovic et al found significantly positive role of GIK solution in cardiac surgery patients and concluded that any amount of combination of glucose and insulin concentration can bring this protective effect.</offsets><xref rid="ref22" ref-type="bibr"><offsets xml_i="22837" xml_f="22839" txt_i="11663" txt_f="11665">22</offsets></xref><offsets xml_i="22846" xml_f="23124" txt_i="11665" txt_f="11943"> Another large study concluded that GIK infusion in cardiac surgery patients is associated with better cardiovascular performance, less requirement of inotropes and reduced myocardial injury in early postoperative period without increasing the risk of non-cardiac complications.</offsets><xref rid="ref23" ref-type="bibr"><offsets xml_i="23158" xml_f="23160" txt_i="11943" txt_f="11945">23</offsets></xref><offsets xml_i="23167" xml_f="23303" txt_i="11945" txt_f="12081"> Recent meta-analysis has concluded that peri-operative GIK infusion improve cardiac performance and myocardial injury in CABG patients.</offsets><xref rid="ref24" ref-type="bibr"><offsets xml_i="23337" xml_f="23339" txt_i="12081" txt_f="12083">24</offsets></xref><offsets xml_i="23346" xml_f="23398" txt_i="12083" txt_f="12135"> Another meta-analysis has reported similar effects.</offsets><xref rid="ref25" ref-type="bibr"><offsets xml_i="23432" xml_f="23434" txt_i="12135" txt_f="12137">25</offsets></xref><offsets xml_i="23441" xml_f="23508" txt_i="12137" txt_f="12204"> Our study have shown similar results as compared to these studies.</offsets></p><p><offsets xml_i="23515" xml_f="24504" txt_i="12205" txt_f="13191">In our study, we found significantly positive effects of GIK infusion on release of CKMB enzymes after surgery, inotropic support and intensive care unit (ICU) stay period. In our study, peak post-surgery CKMB levels were 33.40±14.69 IU/L in GIK group and 48.50±19.79 IU/L in non-GIK group (p-value &lt;0.001). The mean duration of inotropic support in GIK group was only 5.50±6.88 hours in GIK group and 8.64±7.74 hours in non-GIK group (p-value 0.008). The patients in GIK group was early extubated as compared to the non-GIK group. Mean ventilation time in GIK group was 5.06±2.39 hours versus 6.55±3.58 hours in non-GIK group (p-value 0.002). Similarly, ICU stay period was also shorter in GIK group as compared to non-GIK group (p-value 0.01). We did not found any detrimental effect of GIK infusion on non-cardiac complications e.g. renal, pulmonary and neurologic complications. So we found significantly positive effects of GIK infusion in coronary artery bypass grafting patients.</offsets></p></sec><sec sec-type="conclusion" id="sec1-5"><title><offsets xml_i="24560" xml_f="24570" txt_i="13193" txt_f="13203">CONCLUSION</offsets></title><p><offsets xml_i="24581" xml_f="24780" txt_i="13204" txt_f="13403">Glucose-insulin-potassium (GIK) infusion has a beneficial role in myocardial protection and is associated with better post-operative outcomes without increasing the risk of non-cardiac complications.</offsets></p><sec id="sec2-1"><title><offsets xml_i="24808" xml_f="24829" txt_i="13404" txt_f="13425">Authors` Contribution</offsets></title><p><bold><offsets xml_i="24846" xml_f="24849" txt_i="13426" txt_f="13429">SA:</offsets></bold><offsets xml_i="24856" xml_f="24905" txt_i="13429" txt_f="13474"> Conceived, designed, &amp; wrote the manuscript.</offsets></p><p><bold><offsets xml_i="24918" xml_f="24922" txt_i="13475" txt_f="13479">RAA:</offsets></bold><offsets xml_i="24929" xml_f="24972" txt_i="13479" txt_f="13522"> Supervision and editing of the manuscript.</offsets></p><p><bold><offsets xml_i="24985" xml_f="24989" txt_i="13523" txt_f="13527">BAQ:</offsets></bold><offsets xml_i="24996" xml_f="25036" txt_i="13527" txt_f="13567"> Did review and helped in data analysis.</offsets></p><p><bold><offsets xml_i="25049" xml_f="25054" txt_i="13568" txt_f="13573">MARB:</offsets></bold><offsets xml_i="25061" xml_f="25108" txt_i="13573" txt_f="13620"> Did data collection, compilation and analysis.</offsets></p></sec></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold><italic>Sources of Funding:</italic></bold> None.</p></fn><fn fn-type="COI-statement"><p><bold><italic>Declaration of Interest:</italic></bold> None.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodi-Pallares</surname><given-names>D</given-names></name><name><surname>Testelli</surname><given-names>MR</given-names></name><name><surname>Fishleder</surname><given-names>BL</given-names></name><name><surname>Bisteni</surname><given-names>A</given-names></name><name><surname>Medrano</surname><given-names>GA</given-names></name><name><surname>Friedland</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction:A preliminary clinical report</article-title><source>Am J Cardiol</source><year>1962</year><volume>9</volume><issue>2</issue><fpage>166</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">13914751</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malmberg</surname><given-names>K</given-names></name><name><surname>Rydén</surname><given-names>L</given-names></name><name><surname>Efendic</surname><given-names>S</given-names></name><name><surname>Herlitz</surname><given-names>J</given-names></name><name><surname>Nicol</surname><given-names>P</given-names></name><name><surname>Waldenstrom</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study):effects on mortality at 1 year</article-title><source>J Am Coll Cardiol</source><year>1995</year><volume>26</volume><issue>1</issue><fpage>57</fpage><lpage>65</lpage><comment>doi:10.1016/0735-1097(95)00126-K</comment><pub-id pub-id-type="pmid">7797776</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritsinger</surname><given-names>V</given-names></name><name><surname>Malmberg</surname><given-names>K</given-names></name><name><surname>Mårtensson</surname><given-names>A</given-names></name><name><surname>Rydén</surname><given-names>L</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><name><surname>Norhammar</surname><given-names>A</given-names></name></person-group><article-title>Intensified insulin-based glycaemic control after myocardial infarction:mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial</article-title><source>Lancet Diabetes Endocrinol</source><year>2014</year><volume>2</volume><issue>8</issue><fpage>627</fpage><lpage>633</lpage><comment>doi:10.1016/S2213-8587(14)70088-9</comment><pub-id pub-id-type="pmid">24831989</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fath-Ordoubadi</surname><given-names>F</given-names></name><name><surname>Beatt</surname><given-names>KJ</given-names></name></person-group><article-title>Glucose-insulin-potassium therapy for treatment of acute myocardial infarction an overview of randomized placebo-controlled trials</article-title><source>Circulation</source><year>1997</year><volume>96</volume><issue>4</issue><fpage>1152</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">9286943</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maroko</surname><given-names>P</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Sobel</surname><given-names>B</given-names></name><name><surname>Bloor</surname><given-names>C</given-names></name><name><surname>Sybers</surname><given-names>H</given-names></name><name><surname>Shell</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion</article-title><source>Circulation</source><year>1972</year><volume>45</volume><issue>6</issue><fpage>1160</fpage><lpage>1175</lpage><comment>doi:10.1161/01.CIR.96.4.1152</comment><pub-id pub-id-type="pmid">5032816</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname><given-names>M</given-names></name><name><surname>Norris</surname><given-names>R</given-names></name><name><surname>Peter</surname><given-names>T</given-names></name><name><surname>Nisbet</surname><given-names>HD</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name></person-group><article-title>The effects of glucose-insulin-potassium on experimental myocardial infarction in the dog</article-title><source>Cardiovasc Res</source><year>1978</year><volume>12</volume><issue>7</issue><fpage>429</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">719656</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazar</surname><given-names>HL</given-names></name><name><surname>Chipkin</surname><given-names>S</given-names></name><name><surname>Philippides</surname><given-names>G</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Apstein</surname><given-names>C</given-names></name></person-group><article-title>Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations</article-title><source>Ann Thorac Surg</source><year>2000</year><volume>70</volume><issue>1</issue><fpage>145</fpage><lpage>150</lpage><comment>doi:10.1016/S0003-4975(00)01317-5</comment><pub-id pub-id-type="pmid">10921699</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazar</surname><given-names>HL</given-names></name><name><surname>Philippides</surname><given-names>G</given-names></name><name><surname>Fitzgerald</surname><given-names>C</given-names></name><name><surname>Lancaster</surname><given-names>D</given-names></name><name><surname>Shemin</surname><given-names>RJ</given-names></name><name><surname>Apstein</surname><given-names>C</given-names></name></person-group><article-title></article-title><source>J Thorac Cardiovasc Surg</source><year>1997</year><volume>113</volume><issue>2</issue><fpage>354</fpage><lpage>362</lpage><comment>doi:10.1016/S0022-5223(97)70333-7</comment><pub-id pub-id-type="pmid">9040630</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straus</surname><given-names>S</given-names></name><name><surname>Gerc</surname><given-names>V</given-names></name><name><surname>Kacila</surname><given-names>M</given-names></name><name><surname>Custovic</surname><given-names>F</given-names></name></person-group><article-title>Glucosa-insulin-potassium (GIK) solution used with diabetic patients provides better recovery after coronary bypass operations</article-title><source>Med Arch</source><year>2013</year><volume>67</volume><issue>2</issue><fpage>84</fpage><lpage>87</lpage><comment>doi:10.1.1.301.6881</comment><pub-id pub-id-type="pmid">24341049</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali-Hassan-Sayegh</surname><given-names>S</given-names></name><name><surname>Mirhosseini</surname><given-names>SJ</given-names></name><name><surname>Zeriouh</surname><given-names>M</given-names></name><name><surname>Dehghan</surname><given-names>AM</given-names></name><name><surname>Shahidzadeh</surname><given-names>A</given-names></name><name><surname>Karimi-Bondarabadi</surname><given-names>AA</given-names></name><etal></etal></person-group><article-title>Safety and efficacy of glucose–insulin–potassium treatment in coronary artery bypass graft surgery and percutaneous coronary intervention</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2015</year><volume>21</volume><issue>5</issue><fpage>667</fpage><lpage>676</lpage><comment>doi:10.1093/icvts/ivv222</comment><pub-id pub-id-type="pmid">26265069</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christakis</surname><given-names>G</given-names></name><name><surname>Fremes</surname><given-names>S</given-names></name><name><surname>Naylor</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Rao</surname><given-names>V</given-names></name><name><surname>Goldman</surname><given-names>B</given-names></name></person-group><article-title>Impact of preoperative risk and perioperative morbidity on ICU stay following coronary bypass surgery</article-title><source>Vascular</source><year>1996</year><volume>4</volume><issue>1</issue><fpage>29</fpage><lpage>35</lpage><comment>doi:10.1016/0967-2109(96)83780-X</comment></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loop</surname><given-names>FD</given-names></name><name><surname>Higgins</surname><given-names>T</given-names></name><name><surname>Panda</surname><given-names>R</given-names></name><name><surname>Pearce</surname><given-names>G</given-names></name><name><surname>Estafanous</surname><given-names>F</given-names></name></person-group><article-title>Myocardial protection during cardiac operations</article-title><source>J Thorac Cardiovasc Surg</source><year>1992</year><volume>104</volume><issue>60</issue><fpage>608</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">1513150</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bothe</surname><given-names>W</given-names></name><name><surname>Olschewski</surname><given-names>M</given-names></name><name><surname>Beyersdorf</surname><given-names>F</given-names></name><name><surname>Doenst</surname><given-names>T</given-names></name></person-group><article-title>Glucose-insulin-potassium in cardiac surgery:a meta-analysis</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>78</volume><issue>5</issue><fpage>1650</fpage><lpage>1657</lpage><comment>doi:10.1016/j.athoracsur.2004.03.007</comment><pub-id pub-id-type="pmid">15511450</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sher-i-Murtaza</surname><given-names>M</given-names></name><name><surname>Baig</surname><given-names>MAR</given-names></name><name><surname>Raheel</surname><given-names>HMA</given-names></name></person-group><article-title>Early outcome of Coronary Artery Bypass Graft Surgery in patients with significant Left Main Stem stenosis at a tertiary cardiac care center</article-title><source>Pak J Med Sci</source><year>2015</year><volume>31</volume><issue>4</issue><fpage>909</fpage><lpage>914</lpage><comment>doi:10.12669/pjms.314.7597</comment><pub-id pub-id-type="pmid">26430428</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeppsson</surname><given-names>A</given-names></name><name><surname>Ekroth</surname><given-names>R</given-names></name><name><surname>Kirnö</surname><given-names>K</given-names></name><name><surname>Milocco</surname><given-names>I</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Nilsson</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Insulin and amino acid infusion after cardiac operations:effects on systemic and renal perfusion</article-title><source>J Thorac Cardiovasc Surg</source><year>1997</year><volume>113</volume><issue>3</issue><fpage>594</fpage><lpage>602</lpage><comment>doi:10.1016/S0022-5223(97)70375-1</comment><pub-id pub-id-type="pmid">9081107</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolli</surname><given-names>R</given-names></name><name><surname>Jeroudi</surname><given-names>MO</given-names></name><name><surname>Patel</surname><given-names>BS</given-names></name><name><surname>Aruoma</surname><given-names>OI</given-names></name><name><surname>Halliwell</surname><given-names>B</given-names></name><name><surname>Lai</surname><given-names>EK</given-names></name><etal></etal></person-group><article-title>Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial“stunning” is a manifestation of reperfusion injury</article-title><source>Circ Res</source><year>1989</year><volume>65</volume><issue>3</issue><fpage>607</fpage><lpage>622</lpage><comment>doi:10.1161/01.RES.65.3.607</comment><pub-id pub-id-type="pmid">2548761</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolli</surname><given-names>R</given-names></name></person-group><article-title>Mechanism of myocardial“stunning”</article-title><source>Circulation</source><year>1990</year><volume>82</volume><issue>3</issue><fpage>723</fpage><lpage>738</lpage><comment>doi:10.1161/01.CIR.82.3.723</comment><pub-id pub-id-type="pmid">2203553</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akao</surname><given-names>M</given-names></name><name><surname>Ohler</surname><given-names>A</given-names></name><name><surname>O'Rourke</surname><given-names>B</given-names></name><name><surname>Marbán</surname><given-names>E</given-names></name></person-group><article-title>Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells</article-title><source>Circ Res</source><year>2001</year><volume>88</volume><issue>12</issue><fpage>1267</fpage><lpage>1275</lpage><comment>doi:10.1161/hh1201.092094)</comment><pub-id pub-id-type="pmid">11420303</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>GJ</given-names></name><name><surname>Auchampach</surname><given-names>JA</given-names></name></person-group><article-title>Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs</article-title><source>Circ Res</source><year>1992</year><volume>70</volume><issue>2</issue><fpage>223</fpage><lpage>233</lpage><comment>doi:10.1161/01.RES.70.2.223</comment><pub-id pub-id-type="pmid">1310443</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tricarico</surname><given-names>D</given-names></name><name><surname>Mallamaci</surname><given-names>R</given-names></name><name><surname>Barbieri</surname><given-names>M</given-names></name><name><surname>Camerino</surname><given-names>DC</given-names></name></person-group><article-title>Modulation of ATP-sensitive K+channel by insulin in rat skeletal muscle fibers</article-title><source>Biochem Biophys Res Commun</source><year>1997</year><volume>232</volume><issue>2</issue><fpage>536</fpage><lpage>539</lpage><comment>doi:10.1006/bbrc.1997.6320</comment><pub-id pub-id-type="pmid">9125217</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doenst</surname><given-names>T</given-names></name><name><surname>Richwine</surname><given-names>RT</given-names></name><name><surname>Bray</surname><given-names>MS</given-names></name><name><surname>Goodwin</surname><given-names>GW</given-names></name><name><surname>Frazier</surname><given-names>O</given-names></name><name><surname>Taegtmeyer</surname><given-names>H</given-names></name></person-group><article-title>Insulin improves functional and metabolic recovery of reperfused working rat heart</article-title><source>Ann Thorac Surg</source><year>1999</year><volume>67</volume><issue>6</issue><fpage>1682</fpage><lpage>1688</lpage><comment>doi:10.1016/S0003-4975(99)00326-4</comment><pub-id pub-id-type="pmid">10391275</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jovic</surname><given-names>M</given-names></name><name><surname>Gradinac</surname><given-names>S</given-names></name><name><surname>Lausevic-Vuk</surname><given-names>L</given-names></name><name><surname>Nezic</surname><given-names>D</given-names></name><name><surname>Stevanovic</surname><given-names>P</given-names></name><name><surname>Milojevic</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Preconditioning with glucose-insulin-potassium solution and restoration of myocardial function during coronary surgery</article-title><source>Gen Physiol Biophys</source><year>2009</year><volume>28</volume><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">19893109</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>DW</given-names></name><name><surname>Pagano</surname><given-names>D</given-names></name><name><surname>Bonser</surname><given-names>RS</given-names></name><name><surname>Rooney</surname><given-names>SJ</given-names></name><name><surname>Graham</surname><given-names>TR</given-names></name><name><surname>Wilson</surname><given-names>IC</given-names></name><etal></etal></person-group><article-title>Improved myocardial protection during coronary artery surgery with glucose-insulin-potassium:a randomized controlled trial</article-title><source>J Thorac Cardiovasc Surg</source><year>2006</year><volume>131</volume><issue>1</issue><fpage>34</fpage><lpage>42</lpage><comment>doi:10.1016/j.jtcvs.2005.05.057</comment><pub-id pub-id-type="pmid">16399292</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name></person-group><article-title>Effect of perioperative glucose-insulin-potassium infusions on the prognosis in patients undergoing coronary artery bypass grafting:a meta-analysis</article-title><source>Chinese J Surg</source><year>2012</year><volume>50</volume><issue>11</issue><fpage>1021</fpage><lpage>1026</lpage><comment>doi:10.3760/cma.j.issn.0529-5815.2012.11.015</comment></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>AM</given-names></name><name><surname>Xiao</surname><given-names>YB</given-names></name><name><surname>Weng</surname><given-names>YG</given-names></name><name><surname>Hetzer</surname><given-names>R</given-names></name></person-group><article-title>Glucose–insulin–potassium therapy in adult patients undergoing cardiac surgery:a meta-analysis</article-title><source>Eur J Cardiothorac Surg</source><year>2011</year><volume>40</volume><issue>1</issue><fpage>192</fpage><lpage>199</lpage><comment>doi:10.1016/j.ejcts.2010.10.007</comment><pub-id pub-id-type="pmid">21075642</pub-id></element-citation></ref></ref-list></back></article>